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Abstract 
Objective: To investigate whether nasal high-frequency oscillatory ventilation (nHFOV) started immediately after 
extubation of mechanically ventilated very low birth weight infants reduces the partial pressure of carbon dioxide 
at 72 h after extubation in comparison with nasal continuous positive airway pressure. This randomised controlled 
single-centre trial aimed to include 68 preterm infants at high risk of extubation failure.
Results: Implementation of the study protocol was feasible. However, from 2015 to 2017, only six patients could be 
recruited, leading to early termination of the trial. The slow recruitment was due to the introduction of new strategies 
to avoid endotracheal mechanical ventilation, which reduced the number of eligible infants. Moreover, the included 
infants failed their extubation more often than anticipated, thereby increasing the required sample size. Based on our 
single-centre experience, we provide information for study planning and discuss the specific requirements for future 
trial protocols on nHFOV. The extubation of high-risk infants into nHFOV could well be beneficial, but a multicentric 
approach is necessary to investigate this hypothesis.
Trial Registration Clinicaltrials.gov NCT02340299, on 16 January 2015
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Introduction
Nasal high-frequency oscillatory ventilation (nHFOV) 
is a promising mode of non-invasive respiratory sup-
port used in preterm infants [1, 2]. Notwithstanding, the 
clinical significance of nHFOV in the treatment of these 
patients remains uncertain, and high-quality data from 
randomised controlled trials (RCTs) is limited [3, 4]. 
Short-term crossover studies and an observational study 
suggested that nHFOV was more effective than nCPAP 
in improving the exhalation of  CO2 [5–7]. To verify this 
hypothesis, we intended to evaluate whether starting 
nHFOV immediately after extubation would reduce the 
partial pressure of carbon dioxide  (pCO2) at 72  h after 
extubation in comparison with nasal continuous positive 
airway pressure (nCPAP) in an RCT of very low birth 
weight (VLBW) infants < 32 weeks’ gestational age (GA). 
This RCT started in 2015, but had to be terminated pre-
maturely due to slow patient recruitment.
In the present research note, we reported the limited 
information available on study feasibility, outcomes and 
adverse events. More importantly, we aimed to provide 
information about trial conduct and recruitment efforts, 
as these information could help future researchers learn 
from the prior experience of our terminated trial [8].
Main text
Methodology
The present single-centre RCT was conducted at the 
Charité University Medical Centre, Berlin, between 1 
January 2015 and 31 December 2017. The study was reg-
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Study population
The study participants were recruited at a tertiary 
referral centre admitting about 170 VLBW infants 
annually. Infants at < 32 0/7  weeks’ GA with a birth 
weight < 1500 g were eligible if they had received endotra-
cheal mechanical ventilation for ≥ 120  h, were deemed 
ready for extubation, and fulfilled the extubation cri-
teria: (1) caffeine treatment according to unit guide-
lines (2)  pCO2 < 65 mmHg with a pH > 7.2 (3) fraction of 
inspired oxygen  (FiO2) of 25–40% to maintain peripheral 
oxygen saturation  (SpO2) at 90–94% (4) time-cycled, 
pressure-controlled ventilation with a peak inspira-
tory pressure ≤ 22  cm  H2O and positive end-expiratory 
pressure (PEEP) ≤ 6  cm  H2O, volume guarantee venti-
lation with working peak pressures ≤ 22  cm  H2O and 
PEEP ≤ 6  cm  H2O, or high-frequency oscillatory venti-
lation with a mean airway pressure  (Pmean) ≤ 12 cm  H2O 
and an amplitude ≤ 30 cm  H2O.
Infants were excluded if they were participants in 
another RCT, had been treated with hydrocortisone, or 
exceeded 28  days of chronological age. Other exclusion 
criteria were major congenital malformation requiring 
surgery, duct-dependent congenital heart disease, or neu-
romuscular disease.
Randomisation
The eligible infants were randomly assigned to receive 
nHFOV (intervention group) or nCPAP (control group). 
An independent statistician and a study nurse performed 
random sequence generation using a 1:1 ratio and vari-
able block sizes. Allocation concealment was ensured by 
numbered opaque envelopes opened immediately prior 
to extubation.
Study intervention
After extubation, appropriately sized binasal prongs 
were applied to the patient (Infant Nasal Prongs, Fisher 
& Paykel Healthcare Ltd., Auckland, New Zealand) and 
connected to a heated humidifier (MR850, Fisher & 
Paykel) and a neonatal ventilator (VN500, Drägerwerk 
AG, Lübeck, Germany, or Leoni Plus, Heinen & Löwen-
stein, Bad Ems, Germany) using the manufacturer-
approved heated-wire ventilatory circuit. The ventilator 
remained the same before and after extubation. In the 
intervention group, nHFOV was provided (frequency 
10 Hz; amplitude 20 cm  H2O; I:E ratio 33:66;  Pmean 8 cm 
 H2O). However, a minimum frequency of 9  Hz, maxi-
mum amplitude of 30  cm  H2O, and maximum  Pmean of 
8  cm  H2O were applied. In the control group, nCPAP 
was provided (CPAP level 8 cm  H2O; flow 7 l/min). The 
maximum CPAP level was 8 cm  H2O and the maximum 
flow 8 l/min. In both groups, the  FiO2 was set to maintain 
 SpO2 at 90–94%. Within the limits, the physician was free 
to adjust ventilator settings.
Rescue treatment
Treatment failure of either nHFOV or nCPAP was 
defined as meeting at least one of the following crite-
ria: (1) a sustained  pCO2 > 80 mmHg and pH < 7.20 con-
firmed by arterial or capillary blood gas analysis despite 
maximum ventilator support (2) an  FiO2 > 0.6 to maintain 
 SpO2 at 90–94% (3) reintubation.
If the nCPAP infants developed treatment failure but 
did not need immediate reintubation, nHFOV was pro-
vided as ‘rescue treatment’. In the nHFOV group, any 
non-invasive rescue treatment could be provided.
Primary and secondary outcomes
The primary outcome was the  pCO2 at 72 h after extuba-
tion. The secondary outcomes were pH, partial pressure 
of oxygen, and base excess at 72 h after extubation, blood 
gas analysis results at 2  h after extubation, successful 
extubation within 72 h, airway obstruction due to highly 
viscous secretions within 72  h, treatment failure within 
7  days, reintubation within 7  days, total duration of 
mechanical ventilation, and total duration of supplemen-
tal oxygen until discharge. Other secondary outcomes 
included rescue treatment and incidences of common 
adverse effects of prematurity.
Sample size calculation, data monitoring, descriptive 
statistics
Assuming a variability of the  pCO2, as previously 
reported for difficult-to-wean preterm infants in our unit 
[7], and a treatment failure rate of 22% within 72 h after 
extubation, we calculated a sample size of 34 patients 
in each study arm to detect a difference in the  pCO2 of 
7  mmHg using a two-sided significance of 0.05 and a 
power of 0.8. No predefined standards existed for peri-
odical data review or early termination of the trial, and 
no Data and Safety Monitoring Board (DSMB) was insti-
tuted. The categorical data was described in numbers and 
percentages, the quantitative data as medians and ranges.
Results
The nHFOV trial was halted on 31 December 2017 due 
to slow recruitment. Within three years, only six patients 
had been included in the study.
From January 2015 to December 2017, a total of 407 
VLBW infants < 32  weeks’ GA survived to 120  h of age 
and were assessed for eligibility. The reasons for their 
exclusion are detailed in Fig.  1. Most infants were not 
eligible for the study because they had either never been 
endotracheally ventilated or had been but for < 120  h. 
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Among the ventilated patients, 92% (211/229) received 
surfactant. Patients excluded due to hydrocortisone 
treatment had a high risk of mortality and morbidity (see 
Additional file 1). Notably, 39 infants were not included 
due to ‘other’ reasons that were mostly not specified in 
the patients’ records. We are aware that these reasons 
Fig. 1 Flow diagram of the progress of the two study groups through the phases of the randomised trial
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comprised participation in another RCT, failure to assess 
study eligibility, failure to approach the parents for con-
sent within the window of opportunity, lack of skilled 
translators, parental disapproval of study participation, 
failure to comply with the complex extubation criteria, 
and accidental extubation.
Table 1 shows the patient characteristics. Two patients 
suffered from an intraventricular haemorrhage (IVH) 
3°–4° prior to randomisation and happened to be ran-
domised to the nCPAP group. All study patients survived 
to discharge. In the nHFOV group, three out of four 
patients were successfully extubated, but one required 
rescue treatment  (Pmean was increased to 10  cm  H2O). 
In the nCPAP group, both patients had to be reintubated 
within 72 h. The primary outcome,  pCO2 72 h after extu-
bation, could therefore only be assessed in the nHFOV 
group and was 65 (52–79) mmHg. Selected secondary 
outcomes are shown in Table 2. Apart from the pre-exist-
ing IVH 3°–4° cases, there were no obvious differences 
in any adverse outcomes. The small number of study 
patients in each group precluded any formal statistical 
comparison. 
Discussion
The present RCT failed due to slow patient recruitment. 
However, we would like to share the experience of our 
single-centre trial to facilitate the design of future multi-
centre RCTs about nHFOV.
Feasibility of the trial protocol
Implementation of the study protocol was feasible. The 
patients included in the trial were at an extremely high 
risk of re-intubation, with 4/6 (67%) reaching the pre-
specified criteria of treatment failure and 3/6 (50%) being 
reintubated. This rate was much higher than anticipated, 
generated early drop-outs before the primary outcome 
assessment, and increased the estimated sample size 
from 34 to 79 patients in each study arm.
Impact of nHFOV on study outcomes
Due to the limited number of study patients, a meaning-
ful outcome assessment was not possible.
Reasons for slow recruitment
The main reason for slow recruitment was new, clini-
cally beneficial treatment strategies to avoid endotracheal 
mechanical ventilation, such as less-invasive surfactant 
application (LISA) [9]. By the start of the nHFOV trial 
in 2015, LISA had just become our routine treatment 
for VLBW infants with respiratory distress syndrome. 
Consequently, less patients fulfilled the study eligibility 
criteria of receiving ≥ 120  h of endotracheal mechanical 
ventilation and requiring a  FiO2 of 25–40% at extubation. 
VLBW infants with complicated clinical courses (e.g. 
IVH 3°–4°, patent ductus arteriosus, abdominal surgery) 
still required prolonged ventilation and a high  FiO2. Many 
of these severely affected patients, however, were not eli-
gible because they had either received hydrocortisone for 
their first extubation attempt or had not been extubated 
at any time within the first 28  days of life (Fig.  1). This 
shows how challenging it is in the era of LISA to target a 
population of infants at high risk of extubation without 
including those receiving postnatal steroids. With regard 
Table 1 Characteristics of  the  study patients, median 
(range) or n (%)
nHFOV (n = 4) nCPAP (n = 2)
At birth






 Birth weight (g) 503 (420–568) 668 (550–786)
 Male 2 (50) 1 (50)
At study entry
 Chronological age (days) 19 (15–28) 16 (13–19)
 Actual weight (g) 667 (475–700) 800 (775–825)
 Surfactant treatment 4 (100) 2 (100)
 Pmean (cm  H2O) 8.5 (8.3–9.5) 8.2 (6.4–10)
 FiO2 (%) 31 (30–38) 26.5 (25–28)
 Intraventricular haemor-
rhage 3°–4°
0 (0) 2 (100)
Table 2 Selected secondary outcomes, median (range) 
or n (%)
a One patient in the nCPAP group had no blood gas analysis due to reintubation 
less than 2 h after extubation.
b Combined outcome of death or moderate to severe bronchopulmonary 
dysplasia
nHFOV (n = 4) nCPAP (n = 2)
Blood gas analysis 2 h after extubation
 pH 7.31 (7.20–7.36) 7.25a
 pCO2 (mmHg) 60 (52–63) 73
a
 pO2 (mmHg) 32 (25–42) 35
a
Other secondary outcomes
 Successful extubation for > 72 h 3 (75) 0 (0)
 Treatment failure 2 (50) 2 (100)
 Successful rescue treatment 1 (25) 0 (0)
 Reintubation 1 (25) 2 (100)
 Highly viscous secretions 2 (50) 0 (0)
 Duration of mechanical ventilation 
(days)
22.5 (15–54) 47 (40–54)
 Duration of supplemental oxygen 
(days)
70 (51–118) 81 (80–82)
 Intraventricular haemorrhage 3°–4° 0 (0) 2 (100)
 Death or moderate to severe bron-
chopulmonary  dysplasiab
1 (25) 1 (50)
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to the infants for whom the reason for exclusion was not 
clearly documented, we now estimate that maximising 
our efforts could have increased the overall recruitment 
to 10–15 patients in the 2015–2017 period. Neverthe-
less, we would have still required more than 30  years 
to include 79 patients in each study arm. The RCT was 
therefore halted prematurely.
Requirements for future trial protocols
There are several key elements that should be considered 
in future RCTs of nHFOV. Most importantly, the inclu-
sion criteria should specifically target infants who might 
benefit from nHFOV. The beneficial effects of nHFOV 
may be difficult to show in mildly affected infants already 
stabilised on nCPAP, which may explain why nHFOV was 
shown to have had no impact on  pCO2 in a recent cross-
over trial [10]. By contrast, the present pilot RCT showed 
that targeting high-risk patients would require a multi-
centric approach.
Second, our experience showed that overly complex 
study inclusion criteria may interfere with recruitment. 
Pragmatic criteria, for example, the inclusion of all 
VLBW infants extubated after postnatal steroid treat-
ment, may facilitate the recruitment of high-risk patients 
in future RCTs.
Third, there is the question of choosing the most 
appropriate primary outcome. A rise in  pCO2 is a reliable 
indicator of respiratory fatigue in patients with pulmo-
nary failure. Nobody knows, however, whether the ben-
eficial effects of nHFOV on gas exchange are reflected by 
the  pCO2 in stable patients as these patients may simply 
decrease their respiratory efforts to keep the  pCO2 at the 
previous level. Work of breathing or the pressure–time 
product would be more sensitive primary outcomes but 
are difficult to measure during neonatal non-invasive 
respiratory support [11]. From a clinical point of view, 
successful extubation or ventilation/perfusion mismatch 
and bronchopulmonary dysplasia assessed in a standard 
oxygen reduction test would be more relevant outcomes 
[12], but these would require larger sample sizes.
Fourth, future trials should assess potential side effects 
of nHFOV, such as upper airway obstruction due to 
highly viscous secretions [1]. Notably, a recent in  vitro 
study showed that this effect may occur due to impaired 
oropharyngeal gas conditioning in the presence of vigor-
ous nHFOV settings [13].
Fifth, future RCTs should institute clear stopping rules 
and a DSMB to facilitate decisions regarding the continu-
ation, modification, or termination of the trial.
Finally, it should be mentioned that nHFOV may be 
beneficial in the primary treatment of respiratory dis-
tress syndrome [14], but a multicentre RCT of very pre-
term infants of 24 to 28 weeks’ GA would be necessary to 
investigate this in more detail [15]. NHFOV may also be 
an effective rescue treatment in infants with nCPAP fail-
ure, but again, a multicentric approach would be needed 
to investigate this hypothesis [16].
Limitations of this RCT 
• New treatment strategies to avoid endotracheal ven-
tilation reduced the number of eligible patients.
• Complex inclusion criteria interfered with patient 
recruitment.
• The treatment failure rate was higher than expected.
• There were no predefined criteria for trial termina-
tion and no DSMB.
• The trial was halted prematurely due to slow patient 
recruitment.
Additional file
Additional file 1. Patient characteristics and outcomes of very low birth 
weight infants < 32 weeks’ gestational age ventilated for ≥ 120 h, who 
were excluded from the study due to hydrocortisone treatment (n = 10).
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